Enlivex (ENLV) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Enlivex Therapeutics has announced the successful dosing of the first patient in a Phase I trial to test Allocetra, a potential new treatment for psoriatic arthritis. The study aims to recruit six patients unresponsive to conventional therapies, exploring Allocetra’s safety and therapeutic effects. This development could position Enlivex at the forefront of addressing significant unmet needs in a growing psoriatic arthritis market.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
